Breast Cancer Clinical Trial
— CONFIGUREOfficial title:
Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy (CONFIGURE)
Verified date | September 2023 |
Source | Varian, a Siemens Healthineers Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a feasibility study investigating the image quality of a new, high-performance cone beam CT (CBCT) used for on-couch imaging during radiotherapy treatments.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 18, 2023 |
Est. primary completion date | August 18, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The patient will be treated with external beam photon radiotherapy at Maastro for head-and-neck cancer, stage I lung cancer, stage II-IV lung cancer, left breast cancer, or tumours in the abdominal or pelvic region. - Age = 18 years - Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician - Provision of written informed consent Exclusion Criteria: - Patient is pregnant |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht Radiation Oncology | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Varian, a Siemens Healthineers Company |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Image quality | Comparison of image quality produced by the novel cone-beam CT imaging system to the quality of standard cone-beam CT imaging and to that of conventional CT images used for radiotherapy planning purposes. For this objective, the image contrast-to-noise ratio (CNR) will be evaluated. CNR is frequently used to measure image quality. | Within 1 month from the start of treatment | |
Secondary | Image suitability for radiation dose calculation | For this objective, targets and organs at risk will be delineated on the novel CBCT images acquired for each subject. The treatment plan created for the patient on the planning CT scan will be registered to the novel cone-beam CT dataset, the dose will be recalculated on the standard CBCT as well as the novel cone-beam CT. The delineations of target and OARs will either be copied, deformed or manually delineated on the CBCT images, the radiotherapy dose metrics for specific structures relevant for the anatomical site that is imaged will be compared to dose metrics from the original treatment plan. | Within 1 month from the start of treatment | |
Secondary | Qualitative assessment of novel CBCT images | Qualitative assessment of the novel CBCT images will be obtained by presenting individual novel CBCT images as well as head-to-head comparisons of novel and standard CBCT images from the same patient to radiation oncologists and radiation therapists. The reviewers will be asked to evaluate the images on their suitability for anatomical contouring and patient positioning. Qualitative assessments will be determined using a 5-point Likert scale. | Within 1 month from the start of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |